
    
      Eligible participants for this study must have a diagnosis of neurobehavioral disinhibition
      including aggression, agitation, and irritability that persists after brain injury.

      This is a multicenter, randomized, placebo-controlled study, consisting of up to 12 weeks of
      treatment.
    
  